The evaluation of the efficacy of adalimumab in refractory non-infectious uveitis with ultra-widefield fundus fluorescein angiography.

Autor: Uzlu D; Department of Ophthalmology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey. dilenkh@hotmail.com., Köse B; The State Hospital of Bayburt, Bayburt, Turkey., Akyol N; Department of Ophthalmology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey., Erdöl H; Department of Ophthalmology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey., Günay M; Department of Ophthalmology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey.
Jazyk: angličtina
Zdroj: International ophthalmology [Int Ophthalmol] 2022 Jul; Vol. 42 (7), pp. 2107-2116. Date of Electronic Publication: 2022 Jan 05.
DOI: 10.1007/s10792-021-02209-x
Abstrakt: Aim: To investigate the efficacy of adalimumab in the cases with refractory non-infectious uveitis and evaluate retinal vascular leakage changes on ultra-widefield fundus fluorescein angiography.
Methods: Twenty-three patients with refractory uveitis were included in study.
Results: Forty-four eyes of 23 patients with non-infectious uveitiswere evaluated. Clinically active inflammation was present in 19 eyes (43.18%), while 25 (56.8%) were inactive. The mean drug burden was a 9.91 ± 3.78 (5-21) in baseline, 7.3 ± 4.25 at third and 8.0 ± 4.71 at sixth month (p = 0.022). The mean choroidal thickness was 256.65 ± 43.63 μm in baseline, 240.49 ± 36.73 μm at third and 224.81 ± 34.91 μm at sixth month (p ≤ 0.05). In terms of leakage extend, leakage was initially present in a mean of 2.95 ± 4.55 clock hours, 2.41 ± 3.91 at third and 1.76 ± 3.44 at sixth month (p < 0.001).
Conclusion: Adalimumab was found to be effective in establishing inflammation control by reducing drug burden, controlling retinal vascular leakage and choroidal inflammation in refractory uveitis.
(© 2022. The Author(s), under exclusive licence to Springer Nature B.V.)
Databáze: MEDLINE
Externí odkaz: